Skip to main content
S&P 5007,709.24+1.85%DOW53,290.92+2.90%NASDAQ25,920.27+2.16%BTC$80,327.00+3.48%ETH$2,425.85+5.66%GOLD$4,078.60+3.51%OIL$87.62-8.81%
Smart Investors Daily
SID Premium
ED

NASDAQ · EDIT

Editas Medicine, Inc.

Healthcare · Biotechnology

$2.60

Up+$0.12 (+4.42%)

Updated Nov 4, 2026, 5:44 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
217.72M
P/E ratio
-0.91
Dividend yield
0.00%
52-week range
$1.98 – $3.94
Volume
1.76M
Avg. volume
2.47M

Price performance · EDIT

EDIT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

EDIT closed at $2.60 after 21 trading sessions, down 4.76% for the selected period.

Last close
$2.60
Period change
-4.76%
Period low
$2.27
Period high
$2.95
Daily close
View OHLC price history
EDIT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$2.61$2.71$2.57$2.601.76M
Nov 2, 2026$2.71$2.7782$2.55$2.571.24M
Oct 30, 2026$2.89$2.92$2.60$2.672.91M
Oct 29, 2026$2.945$2.98$2.86$2.933.23M
Oct 28, 2026$2.59$2.96$2.54$2.954.43M
Oct 27, 2026$2.41$2.61$2.37$2.603.08M
Oct 26, 2026$2.39$2.445$2.36$2.401.35M
Oct 23, 2026$2.44$2.45$2.30$2.401.31M
Oct 22, 2026$2.47$2.58$2.45$2.491.07M
Oct 21, 2026$2.59$2.60$2.50$2.511.14M
Oct 20, 2026$2.40$2.665$2.35$2.582.27M
Oct 19, 2026$2.38$2.43$2.27$2.422.01M
Oct 16, 2026$2.44$2.47$2.33$2.351.55M
Oct 15, 2026$2.26$2.465$2.25$2.441.86M
Oct 14, 2026$2.44$2.475$2.245$2.272.83M
Oct 13, 2026$2.73$2.73$2.44$2.4452.45M
Oct 12, 2026$2.90$2.91$2.73$2.751.3M
Oct 9, 2026$2.85$2.97$2.71$2.903.09M
Oct 8, 2026$2.79$2.945$2.69$2.846.07M
Oct 7, 2026$2.71$2.845$2.659$2.752.26M
Oct 6, 2026$2.85$2.895$2.715$2.732.97M

Latest EDIT news

The latest Smart Investors Daily articles mentioning EDIT.

Stock researchCompany · Overview

EDIT research

Overview

Company profile and research snapshot.

Company profile

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.85
Implied upside
—
Analysts
—
EDIT recent ratings
DateFirmRatingTarget
Oct 8, 2026Wells FargoOverweight—
Sep 23, 2026GuggenheimBuy—
Aug 18, 2026Ladenburg ThalmannBuy—
May 5, 2026Chardan CapitalBuy—
Mar 10, 2026Jones TradingBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 14, 2026

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany. European Society of Gene and Cell Therapy (ESGCT) CongressTitle: Novel targeted LNP delivery achieved in vivo CAR-T cell generation re

Yahoo · Oct 9, 2026

Is Vertex Stock Worth More Than Its Competitors?

Vertex Pharmaceuticals (VRTX) stock trades at 29.0 times earnings. That valuation prices the company higher than Regeneron and Incyte, two of its biotech peers. Vertex does generate the highest operating margin among its group of five companies, but its sales are growing more slowly than at three of the other four. So how much more are you paying for Vertex, and what do you get for it.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By